Please assess the completion status of the following clinical trial:

Trial Title: The Hemophilia Inhibitor Prevention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male children \>= 4 months and up to 4 years of age.~2. Severe hemophilia A (FVIII \< 0.01 U/ml).~3. No evidence of an inhibitor i.e. anti-FVIII \< 0.6 B.U.~4. No more than 3 FVIII exposures (Factor VIII concentrate, cryoprecipitate, or fresh frozen plasma), including circumcision.~Exclusion Criteria:~1. Acquired hemophilia or any bleeding disorder other than hemophilia A.~2. Treatment with clotting factor or emicizumab previously.~3. Use of an experimental drug(s).~4. Surgery anticipated in the next 48 weeks.~5. Life expectancy less than 5 years.~6. Parent/caretaker unable or unwilling to keep a personal diary of bleeding frequency and study drug treatment, make monthly visits and blood draws at weeks 4, 12, 24, 36, and 48.~7. Other illness, condition or reason in the opinion of the investigator that would make the patient unsuitable for the trial.

- Gender: MALE
- Minimum Age: 4 Months
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Eloctate (Type: ACTIVE_COMPARATOR): Arm A: Eloctate 65 IU/kg will be administered weekly by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued up to 48 weeks.
- Emicizumab (Type: EXPERIMENTAL): Arm B: Emicizumab 1.5 mg/kg will be administered weekly by subcutaneous injection (following 3 mg/kg/wk x4 induction) in previously untreated children with severe hemophilia A beginning before the first bleed and continue up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).